Back to Search Start Over

Liver Transplantation for Metamizole induced Acute Liver Failure.

Authors :
Pohl J
Bischoff P
Oellinger R
Schoening W
Lurje G
Pratschke J
Horst D
Tacke F
Wree A
Source :
Transplantation proceedings [Transplant Proc] 2022 Sep; Vol. 54 (7), pp. 1854-1858. Date of Electronic Publication: 2022 Aug 04.
Publication Year :
2022

Abstract

Metamizole, or dipyrone, is a frequently prescribed analgetic drug that can cause drug-induced liver injury (DILI). Still, there are only a few metamizole-associated DILI cases (n = 61, including our study) described in the literature. So far liver transplantation has been reported in 6 patients with metamizole-induced acute liver failure. In 2020, a German group described a bigger cohort (n = 23) of metamizole-related DILI. Shortly thereafter, this issue gained wider attention as the German Federal Institute for Drugs and Medical Devices published a Direct Healthcare Professional Communication, emphasizing DILI as a potential adverse event caused by metamizole. We herein report 2 patients that were admitted to our liver transplant center due to acute liver failure (ALF) in April and May 2021. Both patients reported intake of metamizole as pain medication over a few weeks. After ruling out alternative reasons for ALF and fulfilling the King's College criteria both patients received emergency liver transplantations in our center. Pathology assessment of both explants were consistent with metamizole-associated DILI. As illustrated by our 2 cases of metamizole-induced liver failure with subsequent liver transplantation, this rare but presumably often overlooked adverse drug effect of metamizole should be considered as differential diagnosis in cases of cryptogenic liver failure.<br /> (Copyright © 2022 Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1873-2623
Volume :
54
Issue :
7
Database :
MEDLINE
Journal :
Transplantation proceedings
Publication Type :
Academic Journal
Accession number :
35933233
Full Text :
https://doi.org/10.1016/j.transproceed.2022.04.028